Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC

Name: Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC
License: Public Domain

Sun Yat-sen University

ClinicalTrials.gov · Datasets · License: Public Domain

neoadjuvant immunotherapy, nsclc, chemo-free therapy

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 356481
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.